Samsung Biologics Sees Biosimilars As One Of Three Key Pillars
Follows Deal To Take Full Ownership Of Samsung Bioepis From Biogen
Samsung Biologics has reiterated the importance of biosimilars to its business in the wake of its move to buy out partner Biogen’s stake in their Samsung Bioepis biosimilars joint venture.
You may also be interested in...
Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.
Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead
Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.